DBT 12733
Alternative Names: DBT-12733Latest Information Update: 28 Dec 2023
At a glance
- Originator Diverse Biotech
- Developer Diverse Biotech; Duke University
- Class Antineoplastics; Cannabinoids
- Mechanism of Action Cannabinoid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Glioblastoma
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for preclinical development in Glioblastoma in USA
- 26 Oct 2021 DBT 12733 is available for licensing as of 26 Oct 2021. https://diversebiotech.com/?page_id=1964
- 26 Oct 2021 Initial pharmacodynamics data from a preclinical trial in Glioblastoma released by Diverse Biotech